ADVERTISEMENT

Natco Pharma Q4 Review - Revlimid Drives Growth In Revenue: Nirmal Bang

Natco Pharma Q4 Review - Revlimid Drives Growth In Revenue: Nirmal Bang

<div class="paragraphs"><p>Formulations facility of Natco Pharma in Kothur. (Source: Company website)</p></div>
Formulations facility of Natco Pharma in Kothur. (Source: Company website)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

Natco Pharma Ltd.’s Q4 FY22 revenue at Rs 5,969 million was significantly higher than our expectation of Rs 4,504 million.

The revenue beat came on the back of profit share booking from Revlimid sales in the U.S. in Q4 FY22 and gain in market share for generic Revlimid in Canada.

Export formulations sales in Q4 FY22 stood at Rs 4,650 million, which grew by 192% YoY.

The incremental growth in export formulations may be attributable to profit share from Revlimid in the U.S., market share gains from gRevlimid in Canada and gAfinitor in the U.S.

Despite the strong beat in revenue, Natco Pharma reported a net loss of Rs 500 million, which is attributable to inventory write-off and credit loss provision pertaining to Covid-19 products.

Click on the attachment to read the full report:

Nirmal Bang Natco Pharma-Q4FY22 Result Update- 31 May 2022.pdf

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.